M&R Capital Management Inc. raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN – Get Rating) by 500.0% in the 1st quarter, Holdings Channel reports. The firm owned 240 shares of the biopharmaceutical company stock after acquiring an additional 200 shares during the period. M&R Capital Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $ 167,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently made changes to their positions in REGN. Benjamin Edwards Inc. acquired a new position in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $ 33,000. Delos Wealth Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth $ 33,000. Byrne Asset Management LLC acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth $ 34,000. Allworth Financial LP increased its holdings in shares of Regeneron Pharmaceuticals by 71.9% during the fourth quarter. Allworth Financial LP now owns 55 shares of the biopharmaceutical company stock worth $ 35,000 after buying an additional 23 shares in the last quarter. Finally, Rosenberg Matthew Hamilton acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth $ 38,000. Institutional investors and hedge funds own 83.83% of the company stock.
Shares of REGN opened at $ 580.95 on Friday. The company has a current ratio of 4.76, a quick ratio of 4.09 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $ 63.06 billion, a P / E ratio of 8.23, a price-to-earnings-growth ratio of 1.79 and a beta of 0.25. The firm’s fifty day simple moving average is $ 653.86 and its two-hundred day simple moving average is $ 644.19. Regeneron Pharmaceuticals, Inc. has a 12 month low of $ 523.29 and a 12 month high of $ 747.42.
Regeneron Pharmaceuticals (NASDAQ: REGN – Get Rating) last announced its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported $ 11.49 earnings per share for the quarter, beating the consensus estimate of $ 9.37 by $ 2.12. Regeneron Pharmaceuticals had a net margin of 48.06% and a return on equity of 50.10%. The firm had revenue of $ 2.97 billion for the quarter, compared to analyst estimates of $ 2.69 billion. During the same quarter in the prior year, the business earned $ 10.09 earnings per share. The business’s quarterly revenue was up 17.2% compared to the same quarter last year. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 40.63 EPS for the current fiscal year.
In related news, Director Arthur F. Ryan sold 100 shares of the company stock in a transaction dated Friday, April 1st. The shares were sold at an average price of $ 692.81, for a total value of $ 69,281.00. Following the sale, the director now owns 22,282 shares in the company, valued at approximately $ 15,437,192.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Leonard S. Schleifer sold 2,886 shares of the company stock in a transaction dated Thursday, March 31st. The stock was sold at an average price of $ 710.01, for a total transaction of $ 2,049,088.86. Following the completion of the sale, the chief executive officer now owns 465,922 shares in the company, valued at approximately $ 330,809,279.22. The disclosure for this sale can be found here. Insiders have sold 29,334 shares of company stock worth $ 20,660,288 in the last quarter. Company insiders own 11.84% of the company stock.
Several research analysts have recently issued reports on the stock. Barclays upped their price target on shares of Regeneron Pharmaceuticals from $ 700.00 to $ 745.00 and gave the stock an “overweight” rating in a report on Tuesday, April 12th. SVB Leerink assumed coverage on shares of Regeneron Pharmaceuticals in a report on Monday, May 23rd. They set an “outperform” rating and a $ 738.00 price target for the company. Morgan Stanley lowered their price target on shares of Regeneron Pharmaceuticals from $ 620.00 to $ 610.00 and set an “equal weight” rating for the company in a report on Friday, June 3rd. Cowen boosted their price objective on shares of Regeneron Pharmaceuticals from $ 640.00 to $ 645.00 in a research note on Wednesday, April 20th. Finally, Cowen boosted their price objective on shares of Regeneron Pharmaceuticals from $ 640.00 to $ 645.00 in a research note on Wednesday, April 20th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $ 711.05.
About Regeneron Pharmaceuticals: (Get Rating)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN – Get Rating).
Receive News & Ratings for Regeneron Pharmaceuticals Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.